|Mr. Richard J. Daly||Chairman, Chief Exec. Officer, Pres and Interim Principal Financial & Accounting Officer||551.67k||N/A||56|
|Dr. Karl Y. Johe Ph.D.||Co-Founder and Chief Scientific Officer||963.33k||N/A||57|
|Danielle Spangler||Director of Investor Relations||N/A||N/A||N/A|
|Dr. Thomas G. Hazel Ph.D.||Sr. VP of Research||N/A||N/A||N/A|
Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Neuralstem, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.